Author: Deepbio

Three posters will be presented at the AACR Annual Meeting 2024 to spotlight Deep Bio’s pioneering research and advancements in AI within digital pathology.

 

 

SEOUL, SOUTH KOREA, March 28, 2024

Deep Bio, a frontrunner in AI-powered cancer diagnostics, will unveil three distinct research findings at the poster sessions during the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 5-10, 2024, in San Diego, CA. These results validate Deep Bio’s advancements in AI-driven pathology, showcasing how novel AI techniques amplify the company’s proficiency across a spectrum of tissue and cancer types

Sun Woo Kim, CEO of Deep Bio, said, “I am proud to see our research findings being presented at the American Association for Cancer Research (AACR) for the third consecutive year, as we integrate AI into diagnostic pathology to improve pathology workflow and patient care.”

Innovative Research Highlights at AACR:

Poster Presentation: Semi-Automated Ki-67 Index Assessment Using Top-k Hotspot Recommendation in Ki-67 IHC Stained WSIs

1. Session Date & Time: Monday, April 8, 2024, from 9 a.m. to 12:30 p.m.
2. Abstract #: 2308
3. Poster #: 19
4. Poster session: Liquid Biopsy and Precision Oncology
5. Lead Author: Hyeon Seok Yang
6. Presenter: Hyeon Seok Yang
7. Overview: This research uses deep learning and image analysis to evaluate cell analysis and top-K hotspot recommendations. The study was performed on Ki-67 IHC-stained WSIs and compared with the pathologist’s Ki-67 score.

Poster Presentation: Enhancing Multi-organ Frozen Section Cancer Discrimination Model by Sharing Cancer Discrimination and Organ Classification Task

1. Session Date & Time: Tuesday, April 9, 2024, from 9 a.m. to 12:30 p.m.
2. Abstract #: 4916
3. Poster #: 12
4. Poster session: Artificial Intelligence and Machine/Deep Learning 3
5. Lead Author: Joonho Lee
6. Presenter: Joonyeong Cho
7. Overview: This research explores the automated analysis of H&E-stained FS WSIs using deep learning to discriminate cancer and classify organs

Poster Presentation: Morphological Feature Discrepancies in Wild-type vs. BRCA1/BRCA2 Mutated High-grade Serious Ovarian Cancer

1. Session Date & Time: Tuesday, April 9, 2024, from 9 a.m. to 12:30 p.m.
2. Abstract #: 4913
3. Poster #: 9
4. Poster session: Artificial Intelligence and Machine/Deep Learning 3
5. Lead Author: JaeHeon Lee
6. Presenter: Hyunil Kim
7. Overview: This research illustrates significant morphological discrepancies between WT and BRCA1/BRCA2 mutated HGSOC cells, highlighting the impact of these genetic mutations on cell size, shape, and texture.

About Deep Bio

Deep Bio is an AI healthcare company dedicated to advancing the field of cancer pathology. Focusing on deep learning, the company develops cutting-edge In Vitro Diagnostic Software as Medical Devices (IVD SaMDs) to empower pathologists and medical professionals with state-of-the-art tools for more accurate cancer diagnosis and prognosis.

For more information, visit the website: www.deepbio.co.kr.

SEOUL, SOUTH KOREA, March 19, 2024 /EINPresswire.com/ — Four research results will be presented to validate Deep Bio’s pioneering research and breakthroughs in AI advancements in digital pathology.
Link to the Article 

Deep Bio, a leader in AI-driven solutions for cancer diagnostics, announced that four different research results will be presented at the poster presentations during the 2024 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, to be held in Baltimore from March 23 to March 28. The posters will describe Deep Bio’s pioneering advancements in AI-driven pathology, demonstrating how novel AI techniques enhance the company’s expertise across diverse tissue and cancer types.

Sun Woo Kim, CEO of Deep Bio, said, “With the increasing demand for advanced medical technologies based on AI, digital pathology has recently emerged as a significant topic. We proudly present the meaningful research results of deep-learning-based cancer diagnosis at the world-class pathology conference for six consecutive years since 2018. We will continue our research to ensure that our deep learning technology contributes to a new era of diagnosis, ranging from cancer diagnosis and prognosis to treatment, across various types of cancer.”

Innovative Research Highlights at USCAP:

• Poster Presentation (#167): A Deep Learning-Based Tumor Area Identification Using a Semi-Supervised Approach for IHC Stained Images in Non-Small Lung Carcinoma
o Session Date & Time: March 25, 2024, From 1:00 to 4:30 p.m.
o Lead Author: Yunseob Hwang
o Overview: This research evaluates a semi-supervised approach to cancer area detection models in cMET IHC-stained whole slide images (WSIs) of non-small cell lung cancer (NSCLC). Manually delineating entire cancer areas in large tissues like resection slides remains a labor-intensive task for developing AI models. Due to this fact, this research introduces a simple yet effective semi-supervised learning approach for tumor area segmentation deep learning models using IHC stained images.

• Poster Presentation(#180): Enhancing Multi-organ: Frozen Section Cancer Discrimination Model with Additional Formalin-Fixed Paraffin-Embedded Whole Slide Images
o Session Date & Time: March 26, from 9:30 to 12:00 p.m.
o Lead Author: Joonho Lee
o Overview: This research explores the automated analysis of H&E-stained Frozen Section (FS) WSIs using a deep learning model across various tissue types to enhance the accuracy of FS cancer discrimination. This deep-learning model is specially developed to determine the presence of cancer in H&E-stained FS whole slide images in the Breast, Lung, Stomach, Breast Sentinel Lymph Node, and Prostate, using H&E-stained and Formalin-Fixed Paraffin-Embedded (FFPE) WSIs.

• Poster Presentation(#210): Enhancing Frozen Section Whole Slide image classification by Style transfer with CycleGAN
o Session Date & Time: March 27, from 1:00 to 4:30 p.m.
o Lead Author: Junho Lee
o Overview: This research introduces a style transfer model to transform the delineation of FFPE data into Frozen Section (FS) data, enriching the data and enhancing feature discrimination. Unlike the Formalin-Fixed Paraffin-Embedded (FFPE) tissue slides, the FS Whole Slide Image (WSI) often has low slide quality due to artifacts, leading to inferior prediction performance compared to the FFPE WSI. Therefore, training-styled-transferred FFPE slides can enhance the predictive performance of FS slides at the slide level and improve the discriminative feature of patch-level images.

• Poster Presentation(#173): Storage Optimization for Digital Pathology Images: Super-Resolution based image compression
o Session Date & Time: March 26, from 9:30 to 12:00 p.m.
o Lead Author: Soyeon Jang
o Overview: This research proposes a super-resolution-based image compression technique to reduce storage demands without sacrificing image quality since storing large volumes of digital pathology data requires monetary investment for institutions to process high caseloads.

About Deep Bio

Deep Bio is an AI healthcare company dedicated to advancing the field of cancer pathology. Focusing on deep learning, the company develops cutting-edge In Vitro Diagnostic Software as Medical Devices (IVD SaMDs) to empower pathologists and medical professionals with state-of-the-art tools for more accurate cancer diagnosis and prognosis. Deep Bio is committed to improving cancer treatment decisions and patient outcomes by harnessing the power of artificial intelligence.

For more information, visit the website: www.deepbio.co.kr.

SEOUL, SOUTH KOREA, February 5, 2024 /EINPresswire.com/ — Deep Bio, a pioneer of AI-powered cancer diagnostics solutions, proudly announced the inclusion of DeepDx Prostate in CancerX’s Solutions Catalog. This significant participation positions Deep Bio as a key contributor to CancerX’s inaugural project, which is dedicated to dismantling barriers to digital innovation in oncology.

Link to the Article 

The Solutions Catalog, launched in 2023, represents CancerX’s inaugural concrete initiative, strategically designed for digital transformation to enhance access to cancer care and alleviate financial burdens on patients.

The Solutions Catalog, an integral part of CancerX’s groundbreaking project, is segmented into three key areas: Screening/Diagnosis, Treatment/End-of-Life Care, and Survivorship. It acts as a reference guide showcasing commercialized digital products and solutions in medical institutions across the United States. The CancerX project ensures immediate access to cutting-edge digital cancer diagnostics and treatment solutions from the featured companies in the Solutions Catalog for healthcare organizations nationwide.

The latest update of the CancerX Solutions Catalog features Deep Bio’s AI-powered software, DeepDx Prostate. This groundbreaking solution empowers pathologists to deliver more precise and efficient prostate diagnoses by automating prostate cancer lesion identification, grading, and quantification of tumor proportion measurements. The solution also significantly decreases turnaround times, minimizes subjectivity in diagnosis, and reduces costs associated with overdiagnosis or unnecessary treatments. These groundbreaking features have immense potential to reduce health inequities in cancer care access and alleviate financial strains on patients.

Sun Woo Kim, CEO of Deep Bio, highlights the urgency of tackling prostate cancer, the second-leading cause of death among American men. “The innovative features of DeepDx Prostate have immense potential to reduce health inequities in cancer care access and alleviate financial strains on patients,” Kim emphasizes the positive impacts of DeepDx Prostate in the medical field. “Due to that fact, Deep Bio’s listing in the Solutions Catalog signifies a transformation of the diagnostic landscape but also contributes to escalating the quality of medical services for prostate cancer patients,” he said.

Deep Bio is proud to contribute to CancerX’s mission of advancing cancer care through innovative digital solutions. The collaboration underscores a shared commitment to improving patient outcomes and enhancing the overall landscape of cancer diagnostics and treatment.

For more information, please visit Deep Bio’s website or contact sales@deepbio.co.kr.